13F Data
13F filer · CIK 1637946

General Catalyst Group Management, LLC

CAMBRIDGE, MA · filing since Q4 2017 · last filing Aug 17, 2026
Reported value
$188.5M
+$5.0M vs prior
Positions
14
New / sold out
4 / 2
Added / reduced
3 / 1
Turnover
32.7%
buys $60.9M · sells $83.3M
Top-10 weight
99.0%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewParabilis Medicines, Inc.+1,600,937–+$43.8M
NewOdyssey Therapeutics, Inc.+810,272–+$15.2M
NewDoordash Inc.+2,850–+$525.9K
NewCarvana Co+6,465–+$425.5K
AddedMeta Platforms Inc.+662+100.6%+$372.9K
AddedCoupang Inc.+18,000+49.1%+$312.7K
AddedAmazon.com Inc.+1,300+50.3%+$309.8K

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outSAMSARA INC-2,000,000-100.0%$-63.4M
Sold outGITLAB INC-921,405-100.0%$-19.9M
ReducedFractyl Health, Inc.-7-0.0%$-6

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2017: $13.5MQ1 2018: $12.6MQ2 2018: $34.3MQ3 2018: $28.6MQ4 2020: $2.9BQ1 2021: $2.6BQ2 2021: $2.3BQ3 2021: $2.0BQ4 2021: $2.6BQ1 2022: $1.8BQ2 2022: $1.1BQ3 2022: $1.1BQ4 2022: $889.0MQ1 2023: $965.0MQ2 2023: $1.2BQ3 2023: $1.1BQ4 2023: $1.3BQ1 2024: $1.3BQ2 2024: $1.2BQ3 2024: $1.4BQ4 2024: $1.1BQ1 2025: $887.5MQ2 2025: $4.3BQ3 2025: $3.0BQ4 2025: $221.7MQ1 2026: $183.6MQ2 2026: $188.5M
Q4 2017Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1ArriVent BioPharma, Inc.COM1,494,786$51.9M27.55%
2Parabilis Medicines, Inc.COM1,600,937$43.8M23.24%
3Maplebear, Inc.COM710,711$33.7M17.85%
4Maze Therapeutics, Inc.COM1,035,910$30.9M16.40%
5Odyssey Therapeutics, Inc.COMMON STOCK810,272$15.2M8.04%
6Eikon Therapeutics, Inc.COM305,233$4.0M2.11%
7Fractyl Health, Inc.COM4,884,186$3.9M2.06%
8Ethos Technologies, Inc.CL A74,179$1.3M0.71%
9Coupang Inc.CL A54,677$949.7K0.50%
10Amazon.com Inc.COM3,882$925.2K0.49%
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.